Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Will This 2020 Biotech IPO Crush the Market This Year?
07:11am, Tuesday, 29'th Jun 2021
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in
What's Next For bluebird bio After The U.S. FDA Lifts Hold On Clinical Trials
08:30am, Wednesday, 09'th Jun 2021
We believe that the stock price of bluebird bio (NASDAQ: BLUE), a biotechnology company focused on gene therapies for severe genetic disorders and cancer, looks attractive at current levels of around
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
12:48pm, Tuesday, 08'th Jun 2021
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
Bluebird bio Can Restart Halted Clinical Trials
05:25pm, Monday, 07'th Jun 2021
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.
Bluebird bio stock surges after FDA lifts clinical hold on studies for sickle cell disease treatments
08:50am, Monday, 07'th Jun 2021
Shares of Bluebird bio Inc. leapt 7.2% in premarket trading after the gene therapy company said the U.S. Food and Drug Administration (FDA) lifted the clinical holds on the company's trials for its si
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to
Is bluebird bio a Buy for Summer 2021?
06:55am, Tuesday, 25'th May 2021
With the stock down 54% over the past year, will investors be catching a falling knife if they buy now?
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
10:51am, Friday, 21'st May 2021
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc's (NASDAQ: BLUE) Skysona (elivaldogene autotemce
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
08:05am, Thursday, 13'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell d
bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat
01:31pm, Thursday, 06'th May 2021
bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
03:47pm, Monday, 03'rd May 2021
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird bio Announces May Investor Events
08:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securitie
What Investors Need to Know About This $419,500 CAR-T Cancer Treatment
11:15am, Saturday, 01'st May 2021
Abecma is on the market.
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?
06:10am, Saturday, 01'st May 2021
The competition is starting to heat up, but bluebird is far from finished.
